Kim Tae Gi, Kim Ki Young, Han Jung Bin, Jin Kyung Hyun
Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
Korean J Ophthalmol. 2016 Oct;30(5):326-334. doi: 10.3341/kjo.2016.30.5.326. Epub 2016 Sep 29.
To evaluate the long-term clinical effectiveness and safety of corneal collagen cross-linking (CXL) in progressive keratoconus compared with untreated contralateral eyes.
In this retrospective study, nine eyes of nine patients with progressive keratoconus who received CXL (treatment group) and nine untreated contralateral eyes with keratoconus (control group) were included. All patients were followed for at least 5 years and assessed with best-corrected visual acuity, maximum keratometry, mean keratometry, corneal astigmatism, and corneal thickness. Clinical data were collected preoperatively and at 1, 3, 6, 12, 24, 36, 48, and 60 months, postoperatively.
Mean best-corrected visual acuity improved significantly from 0.58 ± 0.37 logarithm of minimum angle of resolution preoperatively to 0.39 ± 0.29 logarithm of minimum angle of resolution at 5 years after corneal CXL ( = 0.012). There was significant flattening of the maximum keratometry and mean keratometry from preoperative values of 63.39 ± 10.89 and 50.87 ± 6.27 diopter (D) to postoperative values of 60.89 ± 11.29 and 49.54 ± 7.23 D, respectively ( = 0.038, 0.021). Corneal astigmatism decreased significantly from 7.20 ± 1.83 D preoperatively to 5.41 ± 1.79 D postoperatively ( = 0.021). The thinnest corneal thickness decreased from 434.00 ± 54.13 to 365.78 ± 71.58 µm during 1 month after treatment, then increased to 402.67 ± 52.55 µm at 5 years, which showed a statistically significant decrease compared to the baseline ( = 0.020). In the untreated contralateral eyes, mean keratometry increased significantly at 2 years compared with the baseline ( = 0.043).
CXL seems to be an effective and safe treatment for halting the progression of keratoconus over a long-term follow-up period of up to 5 years in progressive keratoconus.
评估角膜胶原交联术(CXL)治疗进展性圆锥角膜的长期临床疗效和安全性,并与未治疗的对侧眼进行比较。
在这项回顾性研究中,纳入了9例进展性圆锥角膜患者的9只接受CXL治疗的眼睛(治疗组)和9只未治疗的对侧圆锥角膜眼睛(对照组)。所有患者均随访至少5年,并通过最佳矫正视力、最大角膜曲率、平均角膜曲率、角膜散光和角膜厚度进行评估。术前以及术后1、3、6、12、24、36、48和60个月收集临床数据。
最佳矫正视力平均值从术前的0.58±0.37最小分辨角对数显著提高到角膜CXL术后5年的0.39±0.29最小分辨角对数(P = 0.012)。最大角膜曲率和平均角膜曲率从术前的63.39±10.89和50.87±6.27屈光度(D)分别显著变平至术后的60.89±11.29和49.54±7.23 D(P = 0.038,0.021)。角膜散光从术前的7.20±1.83 D显著降低至术后的5.41±1.79 D(P = 0.021)。治疗后1个月内最薄角膜厚度从434.00±54.13降至365.78±71.58 µm,然后在5年时增加至402.67±52.55 µm,与基线相比有统计学显著降低(P = 0.020)。在未治疗的对侧眼中,平均角膜曲率在2年时与基线相比显著增加(P = 0.043)。
在长达5年的长期随访中,CXL似乎是一种有效且安全的治疗方法,可阻止进展性圆锥角膜的进展。